Organisation paid for research Program year 2025 Source: CMS Open Payments

June DO PC

Neither a doctor nor a teaching hospital

Research payments

$1,712,290

247 payments

Through program year 2025, June DO PC is reported as receiving $1,712,290 in research payments, across 247 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$231,086	21
2024	Research	$433,382	14
2023	Research	$88,177	31
2022	Research	$148,365	38
2021	Research	$238,325	48
2020	Research	$329,870	67
2019	Research	$243,086	28

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $593,258 8 payments
AbbVie, Inc. $465,922 102 payments
GlaxoSmithKline, LLC. $340,997 56 payments
Ucb SA $120,585 18 payments
Janssen Research & Development, LLC $67,375 16 payments
Gilead Sciences, Inc. $44,328 12 payments
Genentech, Inc. $28,067 2 payments
Hoffmann-La Roche Limited $20,803 5 payments
Pfizer Inc. $17,804 17 payments
GRT US Holding, Inc. $8,468 9 payments

Studies the money was for Research payments · program years 2019–2025

P4 Uncontrolled Gout FORWARD II $389,415 3 payments
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, $278,304 16 payments
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $169,424 1 payment
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus $119,422 13 payments
M19-130 $118,995 13 payments
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $54,375 14 payments
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $52,544 11 payments
A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis $51,104 3 payments
Study to Investigate Safety and Efficiacy of Obinutuzumab in Patients With Sle $48,870 7 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $41,713 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.